

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

The logo for EuroEyes, featuring the word "EuroEyes" in white sans-serif font on a dark blue rectangular background.

EuroEyes International Eye Clinic Limited

德視佳國際眼科有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1846)

VOLUNTARY ANNOUNCEMENT

UPDATE ON IMPACT OF THE CORONAVIRUS DISEASE 2019 (COVID-19) OUTBREAK ON BUSINESS OPERATIONS

Reference is made to the announcement of EuroEyes International Eye Clinic Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) dated 19 March 2020 (the “**19 March Announcement**”) in relation to the impact of the COVID-19 outbreak on the Group’s business operations. Capitalised terms used herein shall have the same meanings as those defined in the 19 March Announcement unless the context requires otherwise.

Business and Operation in Germany

Subsequent to the 19 March Announcement, the Government of the Federal Republic of Germany (the “**German Government**”) has, since 22 March 2020, put in place social distancing restrictions (the “**Restrictions**”) that were initially due to end on 5 April 2020. The Restrictions were further extended by the German Government on 1 April 2020 to last until at least 19 April 2020.

As disclosed in the 19 March Announcement, the Group’s clinics and consultation centres in Germany have implemented certain preventive measures in view of the COVID-19 outbreak. The Group’s clinics in Germany have also implemented alternative arrangements such as conducting online consultation and live lectures to raise the brand awareness of the Group and connect with potential patients.

While the provision of vision correction services is not prohibited under the Restrictions, having regard to (i) the latest development of the COVID-19 outbreak in Germany and (ii) the balancing of the need to safeguard the wellbeing of the patients and the staff of the Group on the one hand, and the provision of services to new and existing patients on the other, the Directors decided on 31 March 2020 to limit the opening of the Group’s clinics in Munich, Stuttgart, Frankfurt and Düsseldorf in Germany (collectively, the “**Affected Clinics**”) to two days per week.

In addition, from 6 April 2020 onwards, surgeries which are due to be performed at the Affected Clinics will be temporarily suspended until further notice. Patients who are due to have surgeries at the Affected Clinics (the “**Relevant Patients**”) can elect to have their surgeries performed at any of the Group’s five other clinics in Germany (the “**Other Clinics**”). The Directors are of the view that the Other Clinics will have sufficient capacity to treat the Relevant Patients. If any of the Relevant Patients do not elect to have his/her scheduled surgery performed at any of the Other Clinics, the Relevant Patient can reschedule his/her surgery to a later date.

The Directors will continue to closely monitor the development of the COVID-19 outbreak in Germany and decide on a suitable time to resume full operations of the Affected Clinics.

Business and Operation in Denmark

Subsequent to the 19 March Announcement, the Government of the Kingdom of Denmark (the “**Danish Government**”) recommended the temporary closure of the Group’s clinics in Denmark. As a result, the Directors decided on 23 March 2020 to suspend operations of the Group’s clinics in Denmark until further notice. Patients who have already scheduled surgeries at the Group’s clinics in Denmark will have their surgeries re-scheduled after the Group’s clinics in Denmark resume operations.

The Directors will continue to closely monitor the development of the COVID-19 outbreak in Denmark and make further announcements on the resumption of the operations of the Group’s clinics in Denmark in due course.

Business and Operation in the PRC

Since the 19 March Announcement, there has been no material update on the Group’s clinics in the PRC in light of the COVID-19 outbreak.

Continuity of Business

As of the date of this announcement, to the best knowledge and information of the Directors, none of the Group’s medical staff and other non-medical staff in Germany, Denmark and the PRC has been diagnosed with COVID-19.

As disclosed in the 19 March Announcement, the COVID-19 outbreak is expected to have some impact on the Group’s business operations, but it is still premature to assess or estimate the overall impact on the Group’s financial performance given the rapidly changing situation.

The Group will continue to regularly monitor the development of the COVID-19 outbreak and assess its impact on the operations and financial performance of the Group. The Group will adopt appropriate measures when necessary and will make further announcement(s) as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
EuroEyes International Eye Clinic Limited
Leung Ting Cheung
Company Secretary

Hong Kong, 3 April 2020

As at the date of this announcement, the board of Directors comprises Dr. Jørn Slot Jørgensen, Dr. Markus Braun, Dr. Ralf-Christian Lerche, Prof. Dr. Thomas Friedrich Wilhelm Neuhann, Mr. Jannik Jonas Slot Jørgensen as executive Directors; Mr. Marcus Huascar Bracklo as non-executive Director; Mr. Hans Helmuth Hennig, Mr. Zhengzheng Hu and Mr. Philip Duncan Wright as independent non-executive Directors.